BV100 (300 mg)
BV100 (300 mg) is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
0
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
1 of 1 finished
0.0%
0 ended early
2
trials recruiting
3
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Single Centre, Open-label, 2-period Fixed-sequence, Phase I Clinical Study to Evaluate the Effect of BV100 on the Pharmacokinetics of Polymyxin B in Healthy Volunteers
Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex
To Evaluate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of BV100
Clinical Trials (3)
A Single Centre, Open-label, 2-period Fixed-sequence, Phase I Clinical Study to Evaluate the Effect of BV100 on the Pharmacokinetics of Polymyxin B in Healthy Volunteers
Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex
To Evaluate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of BV100
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3